Data featured in an ASH oral presentation; LINKER-MM4 is the first clinical trial to evaluate a BCMAxCD3 bispecific monotherapy in NDMM and is part of a broad clinical development program evaluating ...

It places greater financial burden on children, seniors and the poor by delaying or denying claims necessary for preventive ...

When it comes to possible development corporation projects, some are small, some are big and some are truly massive ...

“I matter” (Criteria for success) When students co-construct criteria, have choice in the forms their work can take, and can see how their contributions inform peers, communities, or future practice, ...

In early November, Eby came as close as he’s ever been to revealing the “original sin” mentality behind his agenda, stating ...

Here are CBC Books picks for the top Canadian nonfiction of the year!

London police are in the process of updating their detention cells to include biometric health sensors, which are small boxes ...

Invivyd’s latest price target revision marks a meaningful reset in expectations, with fair value rising from $7.33 to $10.00 as analysts factor in greater confidence in the REVOLUTION program and the ...

Gibson Energy's latest analyst revisions paint a more cautious picture, with the consensus price target easing from C$26.42 to C$25.62 even as revenue expectations improve from a projected -4.84% to a ...

In this Q&A, John Kirk, principal regulatory specialist at Veristat, explains how the FDA’s Commissioner’s National Priority ...